Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 914 across all filing types
Latest filing 2024-12-09 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (3838 characters) informing the stock exchanges about the schedule of analyst and investor meetings. It references Regulation 30(6) of SEBI Listing Obligations and Disclosure Requirements Regulations, which governs disclosure of material events. The content is about upcoming meetings to discuss past financial results and publicly available information. There is no actual financial data, detailed report, or transcript included. The document is essentially an announcement of meetings rather than a report or transcript itself. According to the rules, such short announcements about meetings or events fall under Regulatory Filings (RNS) as a general regulatory announcement and do not qualify as an investor presentation or call transcript. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-12-09 English
Schedule of analyst/investor meetings on December 12, 2024.
Regulatory Filings
2024-12-09 English
Disclosure under Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulation, 2015 - Retirement and Completion of Tenure ( One Year ) of Independent Director.
Regulatory Filings
2024-12-06 English
Cessation
Regulatory Filings Classification · 95% confidence The document text is extremely short (1156 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, or other report details. There is no mention of any report type, fiscal period, or financial data. The content appears to be a certification or attestation by an individual, likely an officer or authorized signatory. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-12-03 English
Change in Management
Regulatory Filings Classification · 95% confidence The document text is extremely short (1156 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, or other report details. There is no indication of a full report or detailed financial data. The content resembles an officer certification or attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2024-11-21 English
Disclosure under Regulation 30 of the SEBI (LODR) REGULATIONS, 2015-COMPLETION OF TENURE OF ONE YEAR.
Regulatory Filings
2024-11-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.